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Abstract
Objective: To compare electrical impedance myography (EIM) 50 kHz phase to weight, motor score, paw grip endurance
(PGE), CMAP amplitude, and MUNE for the identification of disease progression and the effect of riluzole in the SOD1 G93A
mouse.
Methods: Twenty-three animals received 8 mg/kg/day riluzole in the drinking water starting at 6 weeks of age; 22 animals
served as controls. Weight, motor score, PGE, CMAP, MUNE, and EIM were performed weekly to evaluate disease
progression.
Results: No difference in clinical disease onset or survival was found between treated and untreated groups. In addition, all
methods failed to identify any beneficial effect of riluzole. Thus, data from all animals were combined for additional
analyses. Of the 4 parameters, EIM phase showed the earliest change from baseline and the most linear decline throughout
the entire measurement period. In addition, EIM phase correlated with PGE, CMAP amplitude, and MUNE (Spearman r=0.92,
0.90, and 0.72, respectively, p,0.01 for all). The rate of EIM phase decline also correlated with individual animal survival
(Spearman r=20.31, p,0.05).
Conclusions: At this dose, riluzole is ineffective in slowing progression of ALS. However, EIM phase shows early linear
declines, supporting its potential as a useful new biomarker for preclinical drug testing.
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Introduction
Outcome measures such as survival or the ALS Functional
Rating Scale-Revised (ALSFRS-R) are used to assess new potential
drug therapies in ALS clinical trials [1–4]. However, such
approaches have limited sensitivity to disease progression and
may require an extended length of time or large numbers of
individuals to find a treatment effect [5]. Accordingly, biomarkers
to more effectively measure disease progression over shorter
periods of time and with fewer patients may offer the prospect of
helping speed Phase 2 clinical trials, ultimately aiding in the
identification of new treatments.
While such tools are especially important in human clinical
trials, similar needs also exist for preclinical studies [6,7]. The
ability to more rapidly and accurately detect a treatment effect in
mice is important since it can speed that therapy’s introduction
into clinical studies. In addition, the expanding array of ALS
animal models demands more efficient tools for identifying
treatment effects. Currently, most preclinical mouse studies rely
on measures such as animal weight, survival, and various
behavioral measures such as the paw grip endurance test or
motor score [7]. Whereas these measures are clearly useful, some
are relatively insensitive (e.g., weight) and following survival means
that at least one-half year is needed to complete any study, the
exact length depending on the model being utilized. Motor unit
number estimation (MUNE) has also been studied to a limited
extent in mice [8], but is not used routinely by most investigators
given that it requires considerable training and is time-consuming
to perform.
One technique that appears to have promise as a biomarker
both in human and animal ALS is electrical impedance
myography (EIM) [9,10]. In EIM, a weak, high-frequency
electrical current is passed across a set of electrodes overlying a
muscle of interest and the consequent surface voltages are
measured [11]. These voltages provide a measure of muscle
pathology including muscle atrophy and the presence of fat and
connective tissue within the muscle. Human studies have shown
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e65976that EIM 50 kHz phase value is very reproducible and very
sensitive to decline in ALS [9,12]; in addition, the rate of
deterioration in ALS correlates to the length of survival, suggesting
that EIM could potentially serve as a surrogate outcome measure
[9]. Similarly, EIM applied to the SOD1 G93A rat model
demonstrated great sensitivity to disease progression as well as a
strong relationship between the rate of decline in EIM and the
length of survival of the animals [10].
Given the need for improved biomarkers for ALS mouse
research, we have recently developed a straightforward, rapid, and
reproducible approach for performing EIM in the mouse hind
limb [13]. In that study, only cross-sectional data was evaluated,
comparing healthy to ALS animals. In this study, we evaluate
longitudinally a group of ALS SOD1 G93A mice treated with
riluzole and a group of untreated animals to determine the ability
of EIM to detect the rate of progression and whether a treatment
effect of riluzole could be identified.
Materials and Methods
Animals
All studies were approved by the Beth Israel Deaconess Medical
Center Institutional Animal Care and Use Committee (IACUC).
Breeding colonies of ALS SOD1 G93A (strain: B6SJL-Tg(SOD1-
G93A)1Gur/J) mice were established from animals obtained from
Jackson Laboratories (Bar Harbor, Maine). Animals were geno-
typed by tail snip and were weaned at 21 days. A total of 47 ALS
SOD1 G93A mice were studied (23 females and 24 males) and fed
a standard diet ad libitum. Animals were monitored on a daily basis
by research staff, evaluating condition of fur, grooming, and the
presence of porphyrin staining. Animals were given gel-packs
(DietGelH 76A, PharmaSer, Framingham, MA) when their limbs
became too weak to reach food. They were sacrificed with an
intraperitoneal dose of Fatal PlusH (Patterson Veterinary Supply,
Inc., Devens, MA) at the point that their hind limbs became
completely paralyzed and they could no longer successfully reach
the gel-pack for feeding. Unfortunately, our IACUC would not
approve the standard approach of waiting for the animal to right
itself after 30 seconds of being placed on its side, and thus this
alternative approach was used for all animals.
Animals were evenly divided into riluzole-treated and untreated
groups and weights were obtained weekly. Our goal was to
perform a high-quality controlled drug study taking into the
account the issues discussed in Scott et al [14].
Treatment
Riluzole (Sigma-Aldrich) was dissolved in the animals’ drinking
water, aiming for a total dose of 8 mg/kg/day based on the study
by Kennel et al [15]. Although this dose was lower than that used
in two other studies of mouse motor neuron disease [16,17], it is
the only dose that demonstrated an actual slowing of disease onset
and a prolongation of survival. Moreover, it was the only dose that
was not found to be ineffective in later studies [14]. Treatment was
initiated at approximately 6 weeks of age in all animals.
Behavioral measurements
A standard motor score assessment was performed to determine
clinical disease onset [7]. A score of 4 was given for animals with
no sign of motor dysfunction; 3 for animals with tremors when
suspended by the tail; 2 when the animals had mild difficulty
ambulating; 1 when they were dragging at least one of their hind
limbs; 0 when both hind limbs were fully paralyzed. The paw grip
endurance test was also performed as previously described [7].
MUNE measurements
Motor unit number estimation (MUNE) was performed using a
TECA Synergy T2 EMG Monitor System (Viasys, Madison, WI)
on the left hind limb stimulating the sciatic nerve at the sciatic
notch and recording via disposable ring electrodes around the
entire distal leg, with a ground electrode placed on the right hind
paw, as previously described [8]. All MUNE was performed by a
single individual (JL) using the standard incremental method [8].
Briefly, a supramaximal compound motor action potential
(CMAP) was obtained; then, the stimulus intensity was reset to
zero and gradually increased until the first motor unit potential
(MUP) was identified. Stimulus intensity was further increased
until a total of 20 such steps in amplitude were obtained. From this
data, the average single motor unit potential amplitude was
obtained. The CMAP amplitude was divided by this value to
obtain the MUNE.
Animal EIM measurements
All EIM measurements were performed with the animals placed
under 1% isoflurane anesthesia delivered through a nose cone with
a heating pad underneath the limb to maintain consistent
temperature, as previously described [13]. After the fur was
clipped, a depilatory agent was applied to the skin to remove all
remaining fur; the skin was cleaned with 0.9% saline solution. The
leg was then taped to the measuring surface at an approximately
45u angle extending out from the body, away from the head. A
pinpoint tattoo was placed close to the center of the gastrocnemius
muscle at a point approximately 2/3 of the distance between the
midpoint of the lumbar spine and the base of the heel pad of each
mouse in order to ensure consistent electrode placement over
subsequent measurement sessions.
A fixed rigid 4-electrode array was applied over the gastrocne-
mius muscle [13]. EIM measurements were performed with the
Imp SFB7H bioimpedance spectroscopy device (Impedimed, San
Diego, CA), which obtains impedance data from 3 kHz to 1 MHz.
However, in this analysis we only utilized the single frequency
50 kHz data.
Data analysis
All data were summarized as mean 6 standard error across the
groups. Kaplan-Meier curves were constructed to assess the effect
of riluzole on the length of survival and clinical time of disease
onset (as based on the motor score). Unpaired t-tests were used to
compare the means between 2 groups; Spearman’s correlation
coefficient was calculated to assess the relationship between
survival and rate of decline in MUNE and EIM measurements
as well as for correlations between EIM phase and PGE, CMAP
amplitude and MUNE. For nominal data (e.g., motor score
normal versus abnormal), Fisher exact test was utilized. For all
analyses, significance was accepted at p,0.05, two-tailed.
Results
Two of the 47 animals were excluded from the analysis because
they died at young ages for reasons unrelated to ALS. One animal
escaped and was fatally injured during its retrieval. The other
developed a periorbital infection and the animal research facility
requested its euthanization. Thus, a total of 23 treated and 22
untreated animals were used in the following analyses.
Effect of riluzole
Figure 1 shows Kaplan-Meier curves for both the untreated and
treated animals. The mean clinical disease onset for untreated
animals was no different from the treated animals (120.161.3 days
Electrophysiologic Biomarkers in ALS
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survival for the untreated group was not different from that of the
treated group (136.161.6 days versus 132.461.8 days, respec-
tively, p=0.13, Figure 1b). Based on the standard deviations of the
group survival values and the number of animals in each group,
there had been approximately an 86% power to detect a 7.5 day
prolongation in survival (p,0.05, one-tailed).
As shown is Figure 2a–f, none of the rates of decline for EIM,
PGE, CMAP amplitude, MUNE, weight or motor score showed
significant difference between untreated and treated animals, from
6 weeks of age until death, although there was a non-significant
difference in weight (Figure 2e). This data is also summarized in
Table 1, which shows the individual slopes of decline over time for
each parameter (including EIM resistance and reactance) for
riluzole-treated and untreated animals.
Alterations in parameters over time
Since the riluzole- treated animals did not show a significant
difference from untreated animals in any of the parameters, the
treated and untreated animal data were combined for all the
following analyses. The combined rates of decline are also
summarized in Table 1.
Figure 3a–f provides a comparison of EIM phase, PGE, CMAP,
MUNE, weight and motor score over time with data from both
groups combined. The arrows depict the time of significant
persistent change from baseline (p,0.05) for two consecutive
weeks or longer; this information is also provided in Table 2. Of
note, 50 kHz phase showed a considerably earlier change from
baseline (at 8 weeks) than did CMAP or MUNE, although only
modestly better than PGE (9 weeks). Weight, previously a
commonly used measure, did not show a significant change from
baseline at any point, making it a similarly insensitive parameter
for disease onset. (A decline relative to maximum weight, however,
was present at 18 weeks.) Likewise, the motor score did not show a
significant change until 16 weeks.
Table 2 also summarizes the linearity of the decline and the
time of disease onset over the entire period of measurement for
each of the markers. The linearity of decline was quantified by
performing a least-squares fit based on the average data for each
week across the entire measurement period. Then, residuals for
each of the weeks were calculated; the absolute value of these were
taken and averaged for each measure and then divide for the
average value of that parameter across all measurement points,
thus providing a gauge of how each week’s data deviated from the
regression line. As can be seen, EIM phase has by far the smallest
mean residual, putting in numerical terms what is visually
apparent in Figure 3: that EIM data would track very closely
along a fitted line. Thus, although PGE showed a significant
change from baseline at just 9 weeks, its behavior is decidedly non-
linear (which is also visually apparent in Figure 3b.) Even
compared to CMAP, which also has a fairly low average residual,
the EIM residuals were significantly lower (p,0.001); moreover,
CMAP did not become significantly different from baseline until
12 weeks of age.
Correlations between survival and rate of deterioration
Figure 4a–d shows the correlation between the mean rate of
deterioration from 6 to 20 weeks for EIM, CMAP, MUNE, and
PGE with survival for that animal. Both EIM phase and CMAP
amplitude fared similarly with correlation coefficients of
R=20.31 and R=20.33, respectively, p,0.05 for both.
Meanwhile, neither the rate of PGE or MUNE deterioration
demonstrated significant correlations. It is important to recall,
however, that the variation in lifespan among the animals is fairly
small and thus demonstrating correlations between the rate of
progression and survival is challenging.
Correlations between EIM phase and other measures
Figure 5a–c shows the correlations between EIM 50 kHz phase
and PGE, CMAP amplitude, and MUNE. For this analysis, the
data from each week was averaged across all the animals. As can
be seen, EIM correlates strongly with all three measures.
Discussion
These results indicate that despite evaluating a number of
parameters, riluzole at an approximate dose of 8 mg/kg/day has
no beneficial effect in SOD1 G93A mice. The complete absence of
an effect of riluzole in these studies may at first seem puzzling,
since earlier studies reported a modest therapeutic effect of riluzole
in ALS mouse models [15–17]. However, more recent work has
indicated the considerable limitations of those studies, and repeat
testing, correcting for those limitations, showed that riluzole was
ineffective at a variety of doses [14]. Our work appears to support
that conclusion.
As can be seen in Figure 3, all the biomarkers are able to follow
disease progression in this ALS mouse model, although weight and
motor score appear especially insensitive to disease status. Of all
the biomarkers, EIM appears to be perhaps the strongest for
several reasons. First, EIM is able to identify a decline in the
muscle at just eight weeks of age, earlier than any of the other
measures. Second, the decline is remarkably linear with very little
Figure 1. Kaplan-Meier Curves showing survival and disease onset based on standard clinical measures. a. Disease onset, b. Survival.
doi:10.1371/journal.pone.0065976.g001
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short periods to determine a rate of progression rather than the
lifespan of an animal. Thus, while PGE endurance shows a
significant difference from baseline just one week later than EIM,
it is very non-linear in the early weeks (Figure 3). CMAP, while
being reasonably linear, does not show a significant change from
baseline until 4 weeks later than EIM. Finally, the rate of decline
of EIM, as well as of CMAP amplitude, but not in MUNE or
PGE, appears to correlate to survival of the animals, thus implying
that the rate of decline in the measure is predictive of an animal’s
eventual time of death.
By correlating EIM to PGE, MUNE and to CMAP amplitude,
we aimed to explore the relevance of the EIM data to these
different parameters. As these analyses reveal, there is a good
correlation with all three measures, supporting that the alterations
EIM detects reflect motor neuron loss, subsequent muscle fiber
atrophy and declining motor function. The major change in EIM
phase is due to reductions in reactance values as the disease
progresses (as suggested by Tables 1 and 2) because resistance
barely alters in these animals over time. This likely reflects the
effects of atrophy with minimal change in the actual composition
of the muscles [11]. Moreover, recent work has also demonstrated
that the current flow in EIM is mainly restricted to the more
superficial regions of the muscle [18]. Thus, we anticipate that
EIM is most sensitive to alterations in the upper layers of the
gastrocnemius muscle, a region that consists of mainly Type 2
Figure 2. Weekly measures for riluzole and non-riluzole treated animals. a. 50 kHz phase, b. Paw grip endurance, c. CMAP amplitude, d.
MUNE, e. weight, f. motor score. Open circles, untreated; closed circles, treated.
doi:10.1371/journal.pone.0065976.g002
Table 1. Rates of decline from 6 weeks onward for EIM, PGE, CMAP amplitude, and MUNE in untreated, treated animals and
combined (treated+untreated) groups.
Untreated Treated p value* Combined
Resistance (V/Week) 0.1361.63 22.2261.06 0.23 21.1260.95
Reactance (V/Week) 3.1960.68 2.5360.53 0.45 2.8460.42
Phase (6/Week) 0.6260.13 0.5660.08 0.67 0.5960.07
Paw grip endurance (sec/Week) 6.7860.59 8.3260.65 0.09 7.1060.41
CMAP (mV/Week) 2.2560.20 2.1760.17 0.76 2.2160.13
MUNE (Motor unit/Week) 3.3860.91 3.6861.23 0.84 3.5460.77
Weight (milligrams/week) 27.4650.4 22.0650.9 0.72 11.3639.7
Motor score (points/week) 0.18960.08 0.18960.08 0.97 0.18960.08
*p values compare rates of decline for treated and untreated groups.
doi:10.1371/journal.pone.0065976.t001
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likely to be vulnerable early in the disease. It may be partially for
this reason that EIM shows such sensitivity to change early in the
disease course [19].
Another interesting observation from this study is the potential
of CMAP amplitude to be a better biomarker for disease
progression than MUNE. MUNE has been the focus of most
electrophysiologic studies in the motor neuron disease realm for a
number of years since it is conceptually appealing, as it offers a
true estimation of the number of motor neurons innervating a
muscle or group of muscles. However, despite improved
approaches for its application, it continues to be more challenging
to perform and interpret, thus requiring far more operator
training, operator decision-making, and data collection time than
either CMAP or EIM. From our data here, it also appears to be
relatively insensitive to change early in disease. In humans too, the
estimate becomes most consistent in advanced disease when
relatively few motor units remain [20]. CMAP amplitude has
recently been proposed as an alternative biomarker in spinal
muscular atrophy [21] and thus re-evaluating its use as a primary
Figure 3. Combined riluzole and non-riluzole treated animals. a. 50 kHz phase, b. Paw grip endurance, c. CMAP amplitude, d. MUNE, e.
weight, f. motor score. Arrows indicate time of first consistent significant difference from baseline values for that measure.
doi:10.1371/journal.pone.0065976.g003
Table 2. Linearity of progression and time until first consistent significant difference from baseline for the entire cohort of animals
(N=45).
Measure
Normalized mean absolute residual
from fitted line




Paw grip endurance 0.17 9
CMAP amplitude 0.10 12
MUNE 0.15 15
Weight* --
Motor score 0.20 16
*Resistance and weight values did not change significantly from baseline;
{Residuals from fitted line normalized to mean value of that parameter across all weeks of measurement.
doi:10.1371/journal.pone.0065976.t002
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showed similar consistent reductions in the CMAP amplitude [22].
The limitations to this study include the fact that it was not
blinded to the presence or absence of the drug; however, this issue
would probably only be of concern if a treatment effect had been
identified. Second, we studied only a single dose of riluzole that
had previously been shown to be effective [15]. Ideally, it would
have been preferable to study several doses; however, recent work
Figure 4. Correlation of rate of deterioration from 6 weeks of age until death with: a. 50 kHz phase, b. Paw grip endurance, c. CMAP
amplitude, d. MUNE.
doi:10.1371/journal.pone.0065976.g004
Figure 5. Correlation plots of EIM 50 kHz phase with PGE (a), CMAP amplitude (b) and MUNE (c). For this analysis, weekly data from all
45 animals is averaged.
doi:10.1371/journal.pone.0065976.g005
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these animals [14]. Moreover, there is the possibility that any drug,
including riluzole, could display hormetic behavior (an upside-
down U-shaped dose-response curve) [23,24]. In such a situation,
a higher dose may actually be less effective than a lower. Another
limitation of the study is that the interpretation of the validity of
biomarkers using this animal model is challenging since it is
difficult to show that the biomarker correlates to survival because
the animals die over a very short duration of time. Still, significant
correlations were identified, consistent with results found for
SOD1 G93A rats [10]. A final limitation of the study is the lack of
any standardized EIM measurement tool for mice. Thus, in order
to replicate these findings, it will be necessary to develop an array
with an identical footprint to the one used here. However, EIM
measurement tools continue to be developed, and it is expected
that a standardized version for mouse work will be available soon.
Another general limitation of this work is the focus of studying
biomarkers individually rather than combining values to produce
stronger predictors of disease progression. Indeed, recent work by
others has suggested that such composite markers could be more
effective than individual ones in terms of both establishing a rate of
progression and in its predictive abilities. Such work has been
pursued in Alzheimer’s disease [25] and multiple sclerosis [26]. To
do so, however, would require larger sample sizes than those
presented here, such that one set of data could be used to develop
the composite marker and a second sample could be used to test it,
so as to avoid ‘‘overfitting’’ the data. This should remain a goal of
future research in this area.
Based on these results, one additional interesting observation
that deserves closer study is how EIM values change in the early
weeks of observation. It is clear that ALS SOD1 animals are
different from healthy animals from a young age; for example,
changes in motor neuron excitability have been demonstrated as
early as the second post-natal week [27]. The fact that EIM values
start to decline consistently during these early weeks may be
particularly valuable since it could provide a very fast and efficient
means of assessing the efficacy of a new therapy. Proof of this
potential use, however, will require further study, and most
challenging, a truly effective therapy.
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